Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2019.070 | Deep learning in clinical parameters to predict hepatic events |
Prof. WONG Grace Lai-Hung 黃麗虹 |
| 2018.178 | A novel NAFLD-LE model based on liver stiffness measurement and enhanced liver fibrosis (ELF) to predict clinical events in patients with non-alcoholic fatty liver disease |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2018.554 | A Phase 1b Open-Label, Proof of Concept Study to Evaluate the Safety and Efficacy of Novel Hepatitis B Virus (HBV) Combination Therapies in Chronic Hepatitis B (CHB) Subjects | Prof. WONG Grace Lai Hung |
| 2021.443 | Portable liver scans for suspected and confirmed liver diseases |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2022.656 | A Phase 2a, Randomized, Blinded, Multicenter Study Investigating a Combination of AB-729 and VTP-300 in Virologically-Suppressed Chronic Hepatitis B Participants | Prof. WONG Grace Lai Hung |
| 2013.550 | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B | Prof. WONG Grace Lai Hung |
| 2009.381 | Prevention of recurrent idiopathic gastroduoden ulcer bleeding: a double-blind randomized trial | Dr. WONG Grace Lai Hung |
| 2013.551 | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B | Prof. WONG Grace Lai Hung |
| 2013.316 | A randomized controlled trial of a new screening strategy for varices based on liver and spleen stiffness measurement (LSSM) in cirrhotic patients | Dr. WONG Grace Lai Hung |
| 2012.357 | An open-label trial of 48-week peginterferon alfa-2a (PEGASYS) to assess the sustained response of chronic hepatitis B patients with HBeAg seroconversion on nucleot(s)ide analogue therapy | Prof. WONG Grace Lai Hung |
| 2013.105 | A randomized controlled trial on the efficacy of tenofovir disoproxil fumarate (TDF)-switch therapy in chronic hepatitis B patients with incomplete response to entecavir | Dr. WONG Grace Lai Hung |
| 2018.297 | A Phase 2, Randomized, Open-Label, Active-Controlled Study to Evaluate the Safety and Antiviral Activity of GS-9992 Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Chronic Hepatitis B (CHB) Subjects |
Prof. WONG Grace Lai Hung 陳力元教授 |
| 2020.074 | Secular trend of coronavirus infections - a retrospective observational cohort study |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2018.177 | Secular trend of hepatic events in patients with diabetes mellitus - a retrospective observational cohort study |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2020.090 | Serum fibrosis scores based on common laboratory parameters to guide screening strategies for early identification of hepatocellular carcinoma in patients with chronic hepatitis B |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2019.260 | AN OBSERVER BLIND, RANDOMIZED STUDY WITH AN OPEN LABEL PART TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SUBCUTANEOUS ADMINISTRATION OF RO7191863 WITH MULTIPLE DOSES AND DIFFERENT REGIMENS IN VIROLOGICALLY SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B INFECTION |
Prof. WONG Grace Lai Hung 陳力元 |
| 2018.188 | Machine Learning Model to Predict Clinical Events in Patients with History of Peptic Ulcer Bleeding | Dr. WONG Grace Lai Hung |
| 2019.399 | Role of cryoglobulin in patients with chronic kidney disease | Dr. WONG Grace Lai Hung |
| 2018.646 | Disease burden of chronic viral hepatitis in Hong Kong – towards eliminating viral hepatitis by year 2030 according to World Health Organization (WHO) targets | Dr. WONG Grace Lai Hung |
| 2019.348 | Tenofovir alafenamide (TAF) treatment uptake and impact on ALT normalization in patients with chronic hepatitis B in Hong Kong – real-world cohort study (TAF-RW-HK study) | Dr. WONG Grace Lai Hung |
| 2018.647 | Gastrointestinal and hepatic adverse events of immune checkpoint inhibitors (ICI) - a territory-wide observational cohort study | Dr. WONG Grace Lai Hung |
| 2019.690 | Response after End of Treatment with Antivirals in Chronic Hepatitis B | Prof. WONG Grace Lai Hung |
| 2020.310 | A Phase 2a, Multicenter, Single-Blind, Placebo-Controlled Study Evaluating Treatment Intensification with ABI-H0731 in Subjects with Chronic Hepatitis B Infection on Nucleos(t)ide Reverse Transcriptase Inhibitors | Prof. WONG Grace Lai Hung |
| 2025.372 | A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared with Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects with Chronic Hepatitis B Virus Infection (B-SUPREME) | Prof. WONG Grace Lai Hung |
| 2024.002 | A Phase 2a, Open-Label Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Imdusiran (AB-729) in Combination with Intermittent Dosing of Durvalumab, a PD-L1 Monoclonal Antibody, in Subjects with Chronic HBV Infection | Prof. WONG Grace Lai Hung |
| 2023.684 | A phase II clinical study to evaluate the safety, efficacy, and pharmacokinetics of RBD1016 injection in participants with chronic hepatitis B | Prof. WONG Grace Lai Hung |
| 2024.633 | Universal screening for hepatitis delta virus (HDV) in individuals living with HIV/HBV coinfection and HBV-related HCC | Prof. WONG Grace Lai Hung |
| 2025.847 | Multi-Modal Ultrasound Navigation and AI-Assisted Video Summarization for Diagnostic Enhancement | Prof. Wong Grace Lai Hung |
| 2024.361 | Overcoming Inequalities in Health to Eliminate Hepatitis – Real-World Evidence from a Territory-Wide Cohort |
Prof. WONG Grace Lai Hung Lai Hung Grace Wong |
| 2024.313 | A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Cavrotolimod Alone and in Combinations in Subjects with Chronic Hepatitis B Infection | Prof. WONG Grace Lai Hung |
| 2025.296 | A Phase 1b Study Evaluating the Safety and Tolerability of CLB-4000 with or without Peg-IFNα-2a, Nivolumab or Durvalumab in Subjects with Chronic Hepatitis B |
Prof. WONG Grace Lai Hung Grace Wong |
| 2024.057 | A Long-Term Follow-up Study for Subjects with Chronic Hepatitis B Previously Treated with Imdusiran (AB-729) | Prof. WONG Grace Lai Hung |
| 2024.058 | A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-101, an Oral PD-L1 Inhibitor, in Healthy Subjects and Subjects with Chronic HBV Infection | Prof. WONG Grace Lai Hung |
| 2025.802 | A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants with Chronic Hepatitis B Virus Infection | Prof. WONG Grace Lai Hung |
| 2024.115 | Behavior, Aspirations and Treatment needs of people living with hepatitis B | Prof. WONG Grace Lai Hung |
| 2016.140 | Dynamic change of liver and spleen stiffness measurement (LSSM) to predict incident varices in cirrhotic patients |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2015.089 | Dynamic change of LSM-HCC score and enhanced liver fibrosis (ELF) score to predict hepatocellular carcinoma (HCC) in chronic hepatitis B patients receiving antiviral treatment |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2016.005 | REAL-C: Real-World Evidence from the Asia Liver Consortium for HCV |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2014.537 | Residual intrahepatic viral replication and the development of hepatocellular carcinoma in patients with chronic hepatitis B on oral nucleos(t)ide analogues: A longitudinal study with serial serum hepatitis B virus RNA measurement | Dr. WONG Grace Lai Hung |
| 2016.224 | Impact of long-term tenofovir disoproxil fumarate (TDF) treatment on the risk of HCC in patients with chronic hepatitis B related cirrhosis |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2015.121 | Secular trend of etiologies of hepatic events - a retrospective observational cohort study |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2014.690 | Secular trend of etiologies of hepatocellular carcinoma (HCC) - a retrospective observational cohort study | Dr. WONG Grace Lai Hung |
| 2016.595 | Secular trend of viral hepatitis - a retrospective observational cohort study |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2017.419 | Prevention of recurrent ulcer bleeding in patients with idiopathic gastroduodenal ulcer: a double-blind randomised trial on misoprostol combined with lansoprazole versus lansoprazole alone (NRT_MISO Study) |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2017.214 | Risk of hepatocellular carcinoma in patients with chronic hepatitis B achieved complete viral suppression – role of on-treatment hepatitis B surface/core-related antigen (HBsAg/HBcrAg) levels |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2017.421 | Secular trend of deaths - a retrospective observational cohort study |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2021.297 | A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNa in Subjects with Chronic Hepatitis B Virus Infection |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2021.517 | A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects with Chronic Hepatitis B Infection |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2022.509 | Sodium-glucose co-transporter-2 inhibitor (SGLT2i) to prevent of liver complications in patients with chronic hepatitis B and diabetes mellitus: a double-blind, randomised, placebo-controlled trial |
Prof. WONG Grace Lai Hung 黃麗虹教授 |
| 2020.544 | Deep learning of combined clinical data and CT images in patients with chronic viral hepatitis – risk prediction and complication reduction to facilitate eliminating viral hepatitis by year 2030 |
Prof. WONG Grace Lai Hung 黃麗虹 |
Page 40 of 288.